

Table S1 Determined content results of nine constituents (N= 6).

Content (mg g ⁻¹)	S1	S2	S3	S4	S5	S6	S7	S8	S9	S10
DSS	2.46±	2.58±	1.61±	2.53±	2.59±	2.16±	1.52±	1.28±	1.44±	1.23±
	0.07	0.01	0.05	0.02	0.03	0.08	0.07	0.03	0.05	0.03
ProA	0.06±	0.06±	0.07±	0.07±	0.07±	0.12±	0.07±	0.09±	0.09±	0.06±
	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
RosA	2.37±	3.24±	2.80±	5.18±	4.03±	4.93±	4.40±	4.11±	4.58±	2.77±
	0.03	0.05	0.03	0.02	0.08	0.04	0.05	0.02	0.05	0.03
SalB	30.33	27.78	33.38	33.56	41.18	61.05	58.70	49.98	61.61	59.99
	±0.16	±0.23	±0.18	±0.09	±0.27	±0.45	±0.36	±0.27	±0.33	±0.21
SalA	0.49±	0.42±	0.27±	2.78±	1.95±	0.27±	1.17±	1.36±	1.31±	0.99±
	0.01	0.01	0.01	0.02	0.02	0.01	0.01	0.01	0.02	0.01
ET1	0.03±	0.00±	0.17±	3.16±	0.51±	0.26±	0.38±	1.03±	0.88±	0.26±
	0.01	0.00	0.01	0.03	0.01	0.01	0.01	0.01	0.01	0.01
CT	0.91±	0.52±	0.34±	2.77±	1.81±	0.70±	0.77±	1.90±	1.86±	0.56±
	0.01	0.01	0.01	0.03	0.02	0.01	0.01	0.02	0.03	0.01
T1	0.40±	0.14±	0.40±	2.42±	1.89±	0.68±	0.50±	1.12±	1.16±	0.55±
	0.01	0.01	0.01	0.04	0.03	0.01	0.01	0.01	0.01	0.01
T2	0.86±	0.44±	0.68±	3.84±	3.67±	1.15±	0.41±	1.84±	1.90±	1.25±
	0.01	0.01	0.01	0.03	0.05	0.01	0.01	0.02	0.03	0.01
Total (DSS, ProA, RosA, SalB, SalA)	35.70	34.09	38.13	44.12	49.82	68.53	65.87	56.81	69.02	65.05
Total (CT, T1, T2, ET1)	2.20	1.11	1.59	12.19	7.88	2.78	2.06	5.89	5.79	2.61
Total (CT, T1, T2)	2.18	1.11	1.42	9.03	7.37	2.52	1.68	4.87	4.91	2.36
Total (SalB, CT, T1, T2)	32.51	28.89	34.80	42.60	48.55	63.57	60.39	54.85	66.52	62.34
Total (all)	37.90	35.20	39.72	56.32	57.70	71.31	67.93	62.71	74.81	67.66

Table S2 Biopotency assay of ten samples (S1- S10) of SM

Standard and SM	Mass concentration (mg ml ⁻¹)	Bio-potency concentration (U ml ⁻¹)	Inhibition (I%)	Biopotency (estimated)	Biopotency (measured)	Feasible limit (%)
CT	0.004	4	95%	1000		
	0.0032	3.2	85%			
	0.00256	2.56	60%			
	0.002048	2.048	14%			
S1	12	4	46.6%	0.3330	0.1981	29.81%
	9.6	3.2	4.6%			
	7.68	2.56	1.7%			
	6.144	2.048	9.3%			
S2	24	4	65.1%	0.1670	0.1271	22.99%
	19.2	3.2	48.5%			
	15.36	2.56	28.0%			
	12.288	2.048	8.3%			
S3	32	4	62.0%	0.1250	0.1114	58.31%
	25.6	3.2	57.8%			
	20.48	2.56	52.2%			
	16.384	2.048	53.3%			
S4	8	4	65.8%	0.5000	0.3825	20.65%
	6.4	3.2	57.6%			
	5.12	2.56	21.0%			
	4.096	2.048	0.4%			
S5	12	4	96.9%	0.2500	0.2283	18.26%
	9.6	3.2	57.1%			
	7.68	2.56	53.3%			
	6.144	2.048	8.8%			
S6	20	4	87.5%	0.2500	0.2748	32.41%
	16	3.2	78.8%			
	12.8	2.56	65.4%			
	10.24	2.048	55.0%			
S7	24	4	99.4%	0.1670	0.2383	41.31%
	19.2	3.2	90.3%			
	15.36	2.56	87.5%			
	12.288	2.048	81.4%			
S8	10	4	83.9%	0.4000	0.3704	18.70%
	8	3.2	76.5%			
	6.4	2.56	59.7%			
	5.12	2.048	5.7%			
S9	10	4	87.0%	0.4000	0.3516	17.88%
	8	3.2	70.7%			

	6.4	2.56	33.1%			
	5.12	2.048	9.6%			
S10	20	4	96.1%			
	16	3.2	81.9%	0.2000	0.2520	36.94%
	12.8	2.56	80.3%			
	10.24	2.048	68.3%			

Table S3 Biopotency assay of constituents.

Standard and constituents	Mass concentration (mg ml ⁻¹)	Bio-potency concentration (U ml ⁻¹)	Inhibition (I%)	Biopotency (estimated)	Biopotency (measured)	Feasible limit (%)
CT	0.004	4	95%			
	0.0032	3.2	85%	1000		
	0.00256	2.56	60%			
	0.002048	2.048	14%			
DDS	0.8	4	97%			
	0.64	3.2	83%	5.00	4.995	17.51%
	0.512	2.56	52%			
	0.4096	2.048	0.2%			
ProA	0.781	4	95%			
	0.625	3.2	95%	5.12	4.782	15.35%
	0.5	2.56	23%			
	0.4	2.048	0.1%			
RosA	0.3	4	87%			
	0.24	3.2	16%	13.3	9.869	22.85%
	0.192	2.56	11%			
	0.1536	2.048	22%			
SalB	0.2	4	87%			
	0.16	3.2	64%	20.00	18.92	22.70%
	0.128	2.56	58%			
	0.1024	2.048	26%			
SalA	0.3	4	88%			
	0.24	3.2	72%	13.33	13.287	24.14%
	0.192	2.56	59%			
	0.1536	2.048	36%			
ET1	0.1		0		0	
T1	0.1		0		0	
T2	0.1		0		0	




Fig. S1 Coordinate transformation of qualitative response: (A) is representative of the relationship between dose and inhibition rate; (B) is representative of the relationship between logarithmic dose and probit